Announcements Trials
Browse Landscape

Phase

Phase NA 7Phase 3 1Phase 1 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Prostatic Neoplasms 3Hematologic Neoplasms 2Teratoma 1Stroke 1Pulmonary Disease, Chronic Obstructive 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Kidney Failure, Chronic 1Hepatitis B 1Hematopoietic and Lymphatic System Neoplasm 1Endometrial Clear Cell Adenocarcinoma 1Endodermal Sinus Tumor 1Diabetes Mellitus 1Coronary Artery Disease 1Colonic Neoplasms 1Carcinoma, Embryonal 1COVID-19 1Breast Neoplasms 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

Specimen Handling 2Triptorelin Pamoate 1Standard of Care 1Practice Guidelines as Topic 1Bupropion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Hematopoietic and Lymphatic System Neoplasm × Practice Guidelines as Topic × Clear all
NCT06513962 2026-05-05

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

Children's Oncology Group

Phase 3 Recruiting
60 enrolled
Other solid neoplasm

Hematopoietic and Lymphatic System Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡